ASCO 2022 | Predictive markers of response to durvalumab w/nab-paclitaxel + doxorubicin/cyclophosphamide in TNBC

Lajos Pusztai, MD, DPhil, Yale School of Medicine, New Haven, CT, discusses an exploration of predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in basal-like triple-negative breast cancer (TNBC). Markers identified to predict high pathologic complete response (pCR) included mutational burden, which involved a high frequency of immune cells within the tumor microenvironment (TME) and signs of immune activation. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.